Does Calibrate Prescribe Mounjaro® / Tirzepatide?

What Medications Does Calibrate Typically Prescribe?

Calibrate's program is built around FDA-approved GLP-1 receptor agonists combined with a one-year behavioral curriculum covering food, sleep, exercise, and emotional health. Historically, the platform has centered its formulary on semaglutide and liraglutide rather than tirzepatide, though individual prescribers on the platform retain clinical discretion.

Semaglutide: Calibrate's Core Medication

Semaglutide (Ozempic® 0.5 to 2 mg weekly for type 2 diabetes; Wegovy® 2.4 mg weekly for chronic weight management) has been the cornerstone GLP-1 on Calibrate's platform since the company launched. The STEP-1 trial (N=1,961) demonstrated a 14.9% mean body-weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo (P<0.001) [1]. That magnitude of weight loss, combined with broad insurance coverage in some markets, made semaglutide the practical default for telehealth obesity programs.

The FDA approved Wegovy® specifically for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition, in June 2021 [2]. Calibrate's eligibility criteria mirror those thresholds almost exactly.

Liraglutide as a Second-Line Option

Liraglutide (Saxenda® 3.0 mg daily) remains available on some Calibrate plans, primarily for patients who cannot tolerate the weekly injection schedule or who have prior authorization approved for this agent. The SCALE Obesity trial (N=3,731) showed 8.0% mean weight loss at 56 weeks with liraglutide 3.0 mg versus 2.6% with placebo [3]. Liraglutide is a notably less potent option but has a longer track record in obesity medicine going back to its 2014 FDA approval [4].

Does Calibrate Prescribe Tirzepatide (Mounjaro®)?

Tirzepatide prescribing through Calibrate is not guaranteed and requires individual clinical evaluation. Calibrate does not publicly list tirzepatide as a standard formulary drug as of early 2025, but platform physicians can prescribe any FDA-approved medication they deem clinically appropriate.

Why Tirzepatide Availability Varies

Three factors determine whether a Calibrate patient can access tirzepatide:

1. Insurer formulary placement. Zepbound® (tirzepatide for obesity) earned FDA approval on November 8, 2023 [5], but payer coverage lags FDA action by months to years. Many commercial plans still require prior authorization with documented failure on semaglutide or liraglutide first.

2. Supply chain status. The FDA listed both Mounjaro® and Zepbound® on its drug shortage list in 2023 and 2024, which constrained telehealth prescribing [6]. Supply has improved but is not uniform across all U.S. Pharmacies.

3. Prescriber clinical judgment. Board-certified physicians reviewing Calibrate cases may prescribe tirzepatide off-label via Mounjaro® (approved for type 2 diabetes) for weight management, or on-label via Zepbound® for obesity, if they determine it is the best clinical fit.

How to Find Out If Calibrate Will Prescribe It for You

The most direct path is to complete Calibrate's intake process, provide your insurance information, and ask the assigned physician whether tirzepatide is available under your plan. Calibrate's medical team reviews each case individually. Patients who are already on tirzepatide from another prescriber and want to continue through Calibrate should confirm during onboarding, before paying enrollment fees.

Tirzepatide vs. Semaglutide: What the Clinical Data Show

Whether Calibrate prescribes tirzepatide or semaglutide matters clinically. The efficacy gap between the two agents is now well-quantified in randomized data.

SURMOUNT-1 Results

The SURMOUNT-1 trial (N=2,539) tested tirzepatide 5 mg, 10 mg, and 15 mg weekly versus placebo over 72 weeks in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a comorbidity [7]. The 15 mg dose arm produced a mean body-weight reduction of 20.9%. Across all three active doses, weight loss ranged from 15.0% to 20.9%, all statistically superior to placebo (P<0.001) [7]. This was the largest weight-loss effect ever reported in a phase 3 pharmacotherapy trial at the time of publication.

STEP-1 vs. SURMOUNT-1: A Cross-Trial Comparison

Direct cross-trial comparisons carry methodological limits, but the gap in effect size is difficult to dismiss. STEP-1 (N=1,961, 68 weeks) showed 14.9% weight loss with semaglutide 2.4 mg [1], while SURMOUNT-1 showed 20.9% with tirzepatide 15 mg [7]. That 6-percentage-point gap corresponds to roughly 6 additional kilograms lost for a 100 kg patient.

SURMOUNT-5: The Head-to-Head Trial

The most definitive comparison arrived with SURMOUNT-5, a randomized, open-label trial (N=751) published in 2024. Tirzepatide 10 mg or 15 mg weekly produced 20.2% mean weight loss at 72 weeks versus 13.7% with semaglutide 2.4 mg weekly, a difference of 6.5 percentage points (95% CI: 4.3 to 8.7; P<0.001) [8]. The New England Journal of Medicine published the SURMOUNT-5 results, providing the clearest head-to-head evidence that tirzepatide produces meaningfully greater weight reduction than semaglutide at approved doses [8].

Mechanism: Why Tirzepatide May Outperform

Tirzepatide activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, a dual mechanism that semaglutide does not replicate [9]. Research published in Nature Metabolism suggests the GIP component may reduce GLP-1-related nausea while augmenting fat-mass loss, though the precise interaction is still being characterized [10]. Semaglutide is a selective GLP-1 receptor agonist only [11].

Side Effect Profiles: Are They Different?

The two drugs share a class-level gastrointestinal side effect profile. Knowing the differences helps patients and prescribers choose wisely.

Shared GI Effects

Both tirzepatide and semaglutide commonly cause nausea, vomiting, diarrhea, and constipation, especially during dose escalation. In SURMOUNT-1, nausea occurred in 31.0% of the tirzepatide 15 mg group versus 10.9% in placebo [7]. In STEP-1, nausea occurred in 44.2% of the semaglutide group versus 16.0% in placebo [1]. The absolute rates suggest semaglutide may produce marginally more nausea at maximal approved doses, though trial populations are not identical.

Cardiovascular and Metabolic Safety

The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with pre-existing cardiovascular disease and overweight or obesity (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [12]. Tirzepatide's dedicated cardiovascular outcomes trial, SURMOUNT-MMO, is ongoing. However, tirzepatide's glycemic effects are well-documented: the SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg in type 2 diabetes (P<0.001) [13].

Pancreatitis and Thyroid Risk

Both agents carry FDA boxed warnings for thyroid C-cell tumors based on rodent data, and neither is recommended for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [5, 14]. Pancreatitis risk is considered a class effect; patients with a history of pancreatitis should discuss this with their physician before starting any GLP-1 agent.

Calibrate's Program Structure and How Medication Fits In

Calibrate is not simply a prescription service. The program charges a membership fee and pairs any medication with a structured one-year behavioral curriculum.

The Four Pillars

Calibrate's published framework organizes its program around food, sleep, exercise, and emotional health. Each pillar has video lessons and one-on-one coaching calls. The behavioral component is intended to address the root causes of metabolic dysfunction rather than rely on medication alone. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy explicitly states that "lifestyle intervention should accompany all pharmacological therapy for obesity" [15]. Calibrate's structure aligns with that recommendation.

Cost and Insurance Considerations

Calibrate's program fee and medication costs are separate line items. GLP-1 medications without insurance can reach $900 to $1,400 per month at retail. Zepbound® listed at approximately $1,059.87 for a 4-week supply at launch [5]. Calibrate assists members with prior authorization paperwork, but approval is not guaranteed. Patients on high-deductible plans should budget for out-of-pocket costs during the approval period.

Compounded Tirzepatide: A Different Question

Some telehealth platforms have offered compounded tirzepatide during shortage periods. The FDA has released guidance clarifying that once a drug is removed from the shortage list, compounded versions may no longer be legally dispensed by most pharmacies [6]. Calibrate, as a medically supervised program, prescribes FDA-approved branded medications rather than compounded alternatives as a general practice. Patients interested in compounded tirzepatide should ask specifically whether any partner pharmacy on the Calibrate network still offers it under current FDA policy.

Who Is a Good Candidate for Tirzepatide?

Not every patient who qualifies for Calibrate is an ideal tirzepatide candidate. Clinical selection matters.

BMI and Comorbidity Thresholds

The FDA approved Zepbound® for adults with BMI ≥30 or BMI ≥27 with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease [5]. These thresholds are identical to those for Wegovy®, so patients who qualify for one generally qualify for the other on a clinical basis.

Patients With Type 2 Diabetes

Tirzepatide has a particular advantage for patients with comorbid type 2 diabetes. Mounjaro® is FDA-approved specifically for glycemic control in type 2 diabetes, and the SURPASS trial program (six key trials) documented HbA1c reductions of 1.87% to 2.46% across doses [13, 16]. For a Calibrate patient with both obesity and poorly controlled type 2 diabetes, tirzepatide may offer dual benefit in a single weekly injection.

Patients Who Have Not Responded to Semaglutide

The HealthRX clinical team uses a structured medication-switch framework for patients who lose less than 5% of body weight after 16 weeks of maximum-tolerated semaglutide dosing. In this scenario, the framework recommends evaluating tirzepatide as a step-up option, documenting the inadequate response, and submitting a prior-authorization appeal with STEP-1 and SURMOUNT-5 data as clinical support. This approach is consistent with the Obesity Medicine Association's recommendation to individualize pharmacotherapy based on efficacy response rather than defaulting to a fixed step-therapy sequence [17].

Patients who respond adequately to semaglutide but experience significant nausea may also be candidates for a switch, given some evidence that tirzepatide's GIP co-agonism attenuates GI adverse effects at equivalent weight-loss efficacy.

Alternatives to Calibrate for Tirzepatide Access

If Calibrate cannot prescribe tirzepatide under your plan, several other telehealth platforms specialize in GLP-1 access and may have different formulary relationships.

Other Telehealth Options

Platforms including Ro, Sequence (part of WeightWatchers), Found, and Noom Med operate in the GLP-1 prescribing space. Each has different formulary agreements, prior authorization support teams, and cash-pay pricing arrangements. None is universally superior; the right choice depends on your insurance, preferred coaching format, and geographic availability.

Direct Endocrinologist or Obesity Medicine Referral

The American Board of Obesity Medicine (ABOM) maintains a directory of diplomates who specialize in medical weight management. An ABOM-certified physician can prescribe tirzepatide, manage dose escalation, and coordinate with your insurer directly. The Obesity Medicine Association's 2023 guidelines recommend referral to obesity medicine specialists for patients who do not meet weight-loss targets on initial pharmacotherapy [17].

Primary Care Prescribers

Many primary care physicians now prescribe Zepbound® independently. The American Academy of Family Physicians published guidance in 2024 supporting primary care prescribing of GLP-1 agents with appropriate monitoring, including HbA1c, lipids, renal function, and heart rate at baseline and quarterly [18]. A primary care prescriber combined with a separate behavioral program is a lower-cost alternative to all-in-one telehealth platforms for some patients.

Monitoring Requirements While on Tirzepatide

Any program that prescribes tirzepatide, including Calibrate if it adds tirzepatide to its formulary, should follow standard monitoring protocols.

Baseline Labs

Before starting tirzepatide, clinicians should obtain fasting glucose, HbA1c, a complete metabolic panel, a fasting lipid panel, thyroid-stimulating hormone, and a urine albumin-to-creatinine ratio in patients with diabetes or kidney disease risk [15, 16]. Calcitonin levels are not routinely required but may be ordered if thyroid nodules are detected.

Ongoing Assessment

Weight should be documented at each monthly visit. The Endocrine Society recommends assessing efficacy at 16 weeks: if a patient has not lost at least 5% of initial body weight, the clinician should evaluate adherence, consider dose escalation, and discuss alternative agents [15]. Heart rate elevation of 2 to 4 beats per minute is a class-level effect of GLP-1 agents; patients with tachycardia or atrial fibrillation at baseline warrant closer monitoring [1, 7].